BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29147862)

  • 1. Eosinophilia in a peritoneal dialysis patient: Answers.
    Tzvi-Behr S; Frishberg Y; Ben-Shalom E; Rinat C; Becker-Cohen R
    Pediatr Nephrol; 2018 Sep; 33(9):1507-1508. PubMed ID: 29147862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eosinophilia in a peritoneal dialysis patient: Questions.
    Tzvi-Behr S; Frishberg Y; Ben-Shalom E; Rinat C; Becker-Cohen R
    Pediatr Nephrol; 2018 Sep; 33(9):1505. PubMed ID: 29147861
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure.
    Wiggins KJ; Rumpsfeld M; Blizzard S; Johnson DW
    Nephrology (Carlton); 2005 Feb; 10(1):33-6. PubMed ID: 15705179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis.
    Boer WH; Vos PF; Fieren MW
    Perit Dial Int; 2003; 23(1):33-8. PubMed ID: 12691504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biocompatible dialysis fluids for peritoneal dialysis.
    Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
    Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Icodextrin-associated generalized exfoliative skin rash in a CAPD patient: a case-report.
    Liakopoulos V; Georgianos PI; Demirtzi P; Vaios V; Kalathas T; Zebekakis PE
    BMC Nephrol; 2018 Oct; 19(1):293. PubMed ID: 30359230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions.
    Parikova A; Zweers MM; Struijk DG; Krediet RT
    Adv Perit Dial; 2003; 19():186-90. PubMed ID: 14763059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracorporeal ultrafiltration with icodextrin for the treatment of severe overhydration.
    Okada K; Maruyama N; Oikawa O; Yamazaki T; Higuchi T; Matsumoto K
    Perit Dial Int; 2005; 25(5):503. PubMed ID: 16178487
    [No Abstract]   [Full Text] [Related]  

  • 9. Icodextrin and intraperitoneal inflammation.
    Moriishi M; Kawanishi H
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin reactions with the use of icodextrin in peritoneal dialysis patients.
    Vizcaino Castillo B; Beltrán Catalán S; Molina Vila P; Gonzalez Moya M; Noguera-Morel L; Pallardó Mateu LM
    Nefrologia (Engl Ed); 2019; 39(2):211-213. PubMed ID: 30268413
    [No Abstract]   [Full Text] [Related]  

  • 11. Icodextrin-induced acute generalized exanthematous pustulosis in a patient with peritoneal dialysis.
    Liu CH; Chen CC; Sung CC
    Nephrology (Carlton); 2024 Jul; 29(7):442-445. PubMed ID: 38599621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexplained hypotension and exertional dyspnea in a night-cycled peritoneal dialysis patient--a rare form of icodextrin hypersensitivity.
    Onuigbo MA
    Adv Perit Dial; 2014; 30():87-9. PubMed ID: 25338427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Icodextrin: What arguments for and against its use as an osmotic agent in peritoneal dialysis].
    Savenkoff B; Flechon-Meibody F; Goffin É
    Nephrol Ther; 2018 Jun; 14(4):201-206. PubMed ID: 29291942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icodextrin: a review of its use in peritoneal dialysis.
    Frampton JE; Plosker GL
    Drugs; 2003; 63(19):2079-105. PubMed ID: 12962523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe peritoneal mononucleosis associated with icodextrin use in continuous ambulatory peritoneal dialysis.
    Martín J; Sansone G; Cirugeda A; Sánchez-Tomero JA; Muñoz C; Selgas R
    Adv Perit Dial; 2003; 19():191-4. PubMed ID: 14763060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis.
    Touré F; Lavaud S; Mohajer M; Lavaud F; Canivet E; Nguyen P; Chanard J; Rieu P
    Kidney Int; 2004 Feb; 65(2):654-60. PubMed ID: 14717938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dextran antibodies in peritoneal dialysis patients treated with icodextrin.
    Aanen MC; de Waart DR; Williams PF; Out TA; Zweers MM; Krediet RT
    Perit Dial Int; 2002; 22(4):513-5. PubMed ID: 12322824
    [No Abstract]   [Full Text] [Related]  

  • 18. Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload.
    Johnson DW; Arndt M; O'Shea A; Watt R; Hamilton J; Vincent K
    BMC Nephrol; 2001 Dec; 2():2. PubMed ID: 11737871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical considerations when prescribing icodextrin: a narrative review.
    Silver SA; Harel Z; Perl J
    Am J Nephrol; 2014; 39(6):515-27. PubMed ID: 24925229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sterile peritonitis after administration of icodextrin].
    Ekart R; Pecovnik-Balon B; Dvorsak B; Hojs R
    Acta Med Croatica; 2002; 56(4-5):185-7. PubMed ID: 12768899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.